APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points

Area of Science:

• Neuroimaging
• Genetics
• Alzheimer's Disease Research

Background:

• APOE genotype is the strongest genetic risk factor for Alzheimer's disease (AD).
• Conflicting data exists on how APOE influences amyloid-β (Aβ) deposition and biomarker cut-points.
• Florbetapir PET imaging is crucial for assessing Aβ load.

Purpose of the Study:

• To determine the impact of APOE genotype on amyloid measures using florbetapir PET.
• To assess APOE's influence on Aβ deposition patterns and rates.
• To evaluate APOE's effect on biomarker cut-point selection for Alzheimer's disease classification.

Main Methods:

• Analysis of cerebrospinal fluid Aβ1-42 and florbetapir PET data from 1,072 Alzheimer's Disease Neuroimaging Initiative participants.
• Longitudinal assessment using a subset of 623 participants with a two-year follow-up PET scan.
• Evaluation of APOE genotype effects on Aβ distribution, biomarker cut-points, clinical associations, and deposition rates.

Main Results:

• APOEɛ4 genotype significantly influences the pattern and rate of brain amyloid deposition.
• Biomarker cut-points are not modified by APOE genotype when using white matter/brainstem references in florbetapir PET analysis.
• Differences in Aβ biomarker values by APOE genotype are linked to AD neuropathology, particularly in mild cognitive impairment.
• APOE genotype and age, but not gender, are associated with increased Aβ deposition rates.

Conclusions:

• APOEɛ4 carrier status impacts the rate and location of brain amyloid deposition.
• Proper selection of references in florbetapir PET processing ensures APOE genotype does not alter biomarker cut-point selection.
• Understanding APOE's role is vital for accurate Alzheimer's disease diagnosis and clinical trial interpretation.